Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer

• Antonio José Conde-Moreno ^[9] ; Aránzazu González-del-Alba ^[1] ; Fernando López-Campos ^[2] ; Carlos López López ^[3] ; Ovidio Hernando Requejo ^[4] ; Javier de Castro Carpeño ^[5] ; Rodolfo Chicas-Sett ^[10] ; Laura de Paz Arias ^[6] ; Ángel Montero-Luis ^[4] ; Aurora Rodríguez Pérez ^[7] ; Enriqueta Felip Font ^[11] ; José Ángel Arranz Arija ^[8]
  1. [1] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  2. [2] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  3. [3] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  4. [4] Hospital Universitario HM Sanchinarro

     Hospital Universitario HM Sanchinarro

     Madrid, España

     
  5. [5] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  6. [6] Complexo Hospitalario Universitario de Ferrol

     Complexo Hospitalario Universitario de Ferrol

     Ferrol, España

     
  7. [7] Hospital Ruber Internacional

     Hospital Ruber Internacional

     Madrid, España

     
  8. [8] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  9. [9] Departamento de Oncología Radioterápica, Hospital Universitari i Politècnic La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, España
  10. [10] Departamento de Oncología Radioterápica, ASCIRES Grupo Biomédico, Valencia, España
  11. [11] Oncología Médica, Hospital Universitario del Vall d’Hebron, Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 4 (April), 2023, págs. 897-911
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Oligometastatic disease (OMD) defines a status of cancer that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While imaging diagnostic tools have considerably improved in recent years, unidentified micrometastases can still escape from current detection techniques allowing disease to progress. The variety of OMD scenarios are mainly defined by the number of metastases, the biological and molecular tumour profiles, and the timing of the development of metastases. Increasing knowledge has contributed to the earlier and improved detection of OMD, underlining the importance of an early disease control. Based on increasing detection rates of OMD in the current real clinical practice and the lack of standardized evidence-based guidelines to treat this cancer status, a board of experts from the Spanish Societies of Radiation Oncology (SEOR) and Medical Oncology (SEOM) organized a series of sessions to update the current state-of-the-art on OMD from a multidisciplinary perspective, and to discuss how results from clinical studies may translate into promising treatment options. This experts’ review series summarizes what is known and what it is pending clarification in the context of OMD in the scenarios of Non-Small Cell Lung Cancer and Breast Cancer (Part I), and Prostate Cancer and Colorectal Cancer (Part II), aiming to offer specialists a pragmatic framework that might contribute to the improved management of patients.